WO2022134262A1 - 二吡咯甲烯-1-酮类化合物及其制备方法 - Google Patents
二吡咯甲烯-1-酮类化合物及其制备方法 Download PDFInfo
- Publication number
- WO2022134262A1 WO2022134262A1 PCT/CN2021/073783 CN2021073783W WO2022134262A1 WO 2022134262 A1 WO2022134262 A1 WO 2022134262A1 CN 2021073783 W CN2021073783 W CN 2021073783W WO 2022134262 A1 WO2022134262 A1 WO 2022134262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- dipyrrole
- hydrogen
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- -1 phenylthio, phenylsulfinyl Chemical group 0.000 claims abstract description 29
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 7
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims abstract description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- ULUNQYODBKLBOE-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrole Chemical compound C1=CNC(C=2NC=CC=2)=C1 ULUNQYODBKLBOE-UHFFFAOYSA-N 0.000 claims description 8
- 238000006482 condensation reaction Methods 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 238000005815 base catalysis Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract description 3
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 abstract description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000011734 sodium Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- ICSYWXKWNBYRGB-UHFFFAOYSA-N methyl 3-(5-formyl-2,4-dimethyl-1h-pyrrol-3-yl)propanoate Chemical compound COC(=O)CCC1=C(C)NC(C=O)=C1C ICSYWXKWNBYRGB-UHFFFAOYSA-N 0.000 description 4
- PLBQLIFDSMCQBT-UHFFFAOYSA-N methyl 3-(5-formyl-4-methyl-1h-pyrrol-3-yl)propanoate Chemical compound COC(=O)CCC1=CNC(C=O)=C1C PLBQLIFDSMCQBT-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VFUWPNDFAUZGPP-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C)=C1CCSC2=CC=C(C)C=C2)C1=O)=O Chemical compound CC(C)(C)OC(N(CC(C)=C1CCSC2=CC=C(C)C=C2)C1=O)=O VFUWPNDFAUZGPP-UHFFFAOYSA-N 0.000 description 3
- NCYRCRSTMRNVSY-UHFFFAOYSA-N CC(CNC(CCCC1=CC=C(C)C=C1)=S)(OC)OC Chemical compound CC(CNC(CCCC1=CC=C(C)C=C1)=S)(OC)OC NCYRCRSTMRNVSY-UHFFFAOYSA-N 0.000 description 3
- SJPGQNUIGOTOSR-UHFFFAOYSA-N CC(CNC(CCCC1=CC=C(C)C=C1)=S)=O Chemical compound CC(CNC(CCCC1=CC=C(C)C=C1)=S)=O SJPGQNUIGOTOSR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- KOVBNJNMZMTLKX-UHFFFAOYSA-N tert-butyl 5-formyl-3-(3-methoxy-3-oxopropyl)-4-methyl-1H-pyrrole-2-carboxylate Chemical compound COC(=O)CCC=1C(C)=C(C=O)NC=1C(=O)OC(C)(C)C KOVBNJNMZMTLKX-UHFFFAOYSA-N 0.000 description 3
- CJZOSFDKUBPWHD-UHFFFAOYSA-N 2,2-dimethoxypropan-1-amine Chemical compound COC(C)(CN)OC CJZOSFDKUBPWHD-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- VIXWGKYSYIBATJ-UHFFFAOYSA-N pyrrol-2-one Chemical compound O=C1C=CC=N1 VIXWGKYSYIBATJ-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical group CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HBVTUHKUPMJYMD-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonylpyrrolidin-2-one Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)C1CCC(N1)=O HBVTUHKUPMJYMD-UHFFFAOYSA-N 0.000 description 1
- XFTZBWOYWJRJOK-UHFFFAOYSA-N Br.Br.Br.CN(C)C1=CC=CC=C1C Chemical compound Br.Br.Br.CN(C)C1=CC=CC=C1C XFTZBWOYWJRJOK-UHFFFAOYSA-N 0.000 description 1
- QGWBXQXKATYOPE-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C)=C1CCS(C2=CC=C(C)C=C2)(=O)=O)C1=O)=O Chemical compound CC(C)(C)OC(N(CC(C)=C1CCS(C2=CC=C(C)C=C2)(=O)=O)C1=O)=O QGWBXQXKATYOPE-UHFFFAOYSA-N 0.000 description 1
- IBFFRXHPDQIPQY-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C)=C1CCS(C2=CC=C(C)C=C2)=O)C1=O)=O Chemical compound CC(C)(C)OC(N(CC(C)=C1CCS(C2=CC=C(C)C=C2)=O)C1=O)=O IBFFRXHPDQIPQY-UHFFFAOYSA-N 0.000 description 1
- KKTKZJUNAUFMPL-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C)=O)C(CCCC1=CC=C(C)C=C1)=S)=O Chemical compound CC(C)(C)OC(N(CC(C)=O)C(CCCC1=CC=C(C)C=C1)=S)=O KKTKZJUNAUFMPL-UHFFFAOYSA-N 0.000 description 1
- RGYXXZDHZJACIW-UHFFFAOYSA-N CC1=CC=C(CCCC(Cl)=S)C=C1 Chemical compound CC1=CC=C(CCCC(Cl)=S)C=C1 RGYXXZDHZJACIW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the patent of the present invention belongs to the field of medicinal chemistry, and more particularly, the present invention relates to a dipyrrole methan-1-one compound and a preparation method thereof.
- Dipyrrolemethen-1-one compounds are important pharmaceutical intermediates.
- there are not many types of dipyrrolemethen-1-one compounds disclosed and there are few uses for the compounds themselves.
- Research, in addition, the disclosed synthesis method of specific dipyrrole methan-1-one compounds is complicated, for example, the literature Bull.Chem. method, specifically, this document uses 3-p-toluenesulfonylethyl-4-methyl-5-p-toluenesulfonyl 1,5-dihydro-2H-2-pyrrolidone as raw material, in DBU and tributyl Phosphine-catalyzed condensation with pyrrole aldehyde produces dipyrrole-1-ones.
- This route has a long reaction route, low yields in some steps, difficult separation, and requires column chromatography for separation, which is not suitable for industrialization requirements.
- the synthesis process needs to use some expensive reagents such as tributylphosphine, trimethylaniline tribromide, etc., which increases the cost of raw materials, and also needs to use some highly polluting reagents, such as trifluoroacetic acid, DBU, etc., and some highly toxic reagents. , or flammable and explosive reagents such as methanesulfonyl chloride, nitromethane, etc., which limit industrial production.
- the present invention aims to solve the problems existing in the prior art to a certain extent, and for this purpose, provides a new dipyrrole methan-1-one compound, its preparation method and its use.
- the present invention provides a dipyrrole methan-1-one compound, the structural formula of which is shown in formula 1,
- R is selected from one of hydrogen, C 1 -C 5 alkyl and benzyl;
- R 1 is selected from phenylthio, benzenesulfinyl, benzenesulfonyl, p-toluenethio, p-toluenesulfinyl, One of p-toluenesulfonyl;
- R 2 is selected from one of methyl, alkoxycarbonyl, aldehyde, acetoxymethyl, carboxyl and hydrogen.
- R is selected from hydrogen, C 1 -C 5 alkyl;
- R 1 is selected from one of p-toluenethio, p-toluenesulfinyl, and p-toluenesulfonyl;
- R 2 is selected from methyl, alkoxycarbonyl and one of hydrogen.
- the structural formula of the dipyrrole-1-one compound (the compound represented by formula 1) is selected from the following structures:
- the present invention also provides a preparation method of the above compound, which is obtained by the condensation reaction of the compound of formula 2 and the compound of formula 3, and the reaction formula is as follows:
- R is selected from one of hydrogen, C 1 -C 5 alkyl and benzyl;
- R 1 is selected from phenylthio, benzenesulfinyl, benzenesulfonyl, p-toluenethio, p-toluenesulfinyl, One of p-toluenesulfonyl;
- R 2 is selected from one of methyl, alkoxycarbonyl, acetoxymethyl, carboxyl and hydrogen.
- the solvent used in the condensation reaction is selected from one or more of methanol, ethanol, isopropanol, DMSO, DMF, toluene, xylene, tetrahydrofuran and methyltetrahydrofuran.
- the condensation reaction is carried out under base catalysis.
- the base is selected from one or more of sodium hydroxide, potassium hydroxide and DBU.
- the condensation reaction temperature is controlled to be 15-150°C, preferably 70-110°C.
- the molar ratio of the compound of formula 2, the compound of formula 3 and the base is 1:0.5-2:0.2-2, preferably 1:0.8-1.2:0.5-1.
- the present invention also provides the use of the above-mentioned dipyrrolidin-1-one in preparing a medicament for treating tumors.
- the tumor is breast cancer or lung cancer.
- the present invention provides a new dipyrrole melen-1-one compound, which can be used to prepare medicines for the treatment of tumors, such as breast cancer or lung cancer.
- the present invention provides a new preparation method of dipyrrole-1-one compounds, which has simple preparation process, mild conditions, can be carried out at room temperature, and low cost; Compared with the synthesis method, the present invention removes reagents such as tributylphosphine, trifluoroacetic acid, nitromethane, etc., the raw materials are simple and easy to obtain, more economical, safer, easier to separate and purify, and suitable for industrial production.
- tert-butyl 5-formyl-4-methyl-3-methoxycarbonylethyl-2-pyrrolecarboxylate (the compound represented by formula 4) was prepared according to the document Bull.Chem.Soc.Jpn., 1994 , 67, 3088 ⁇ 3093 method, 3,5-dimethyl-4-methoxycarbonylethylpyrrole carboxaldehyde (compound shown in formula 8) is prepared according to the literature J.Chem.Soc., Perkin I, 1987, 265 ⁇ 276 Method preparation, 4-methoxycarbonylethyl-3-methyl-2-pyrrolecarbaldehyde (compound shown in formula 9) was prepared according to the method of Tetrahedron, 1990, 42, 7599, 2,2-dimethoxypropylamine (formula 9) The compound shown in 13) was prepared according to the method of the document Euro.J.Med.Chem., 1995, 30, 931 ⁇ 942; 4-p-toluenethiobut
- Embodiment 11 is a diagrammatic representation of Embodiment 11:
- Anti-tumor activity test The in vitro anti-tumor activity of A-549 breast cancer cells was measured by sulforhodamine B (SRB) method.
- SRB sulforhodamine B
- the A-549 human breast cancer cells in logarithmic growth were inoculated into a 96-well microplate at 90 ⁇ L/well, and after culturing for 24 hours, the compounds 1a, 1b, 1c, 1d, 1e, 1f, The solutions of 1g, 1h, and 1i were 10 ⁇ L/well, each concentration was three replicate wells, and a cell-free zero-adjustment well was also set.
- the compound concentrations of the solutions containing the compounds 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i obtained by the present invention are all 10 -5 M.
- the culture medium was discarded, 100 ⁇ L/well of 10% TCA was added to fix for 1h at 4°C, washed three times with distilled water, and dried naturally.
- the optical density (OD560) value was measured by enzyme label at 560nm wavelength.
- the inhibition rate of the test substance on tumor cell growth was calculated as (OD value of control group-OD value of administration group)/OD value of control group ⁇ 100%.
- the compounds have certain inhibitory activity on A-549 human breast cancer cells at the above concentrations. Therefore, the dipyrrolemen-1-one of the present invention can be used for preparing medicines or leading compounds for treating tumors, especially for treating breast cancer and lung cancer and leading compounds.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (10)
- 根据权利要求1所述的二吡咯甲烯-1-酮类化合物,其特征在于,R选自氢、C 1~C 5烷基;R 1选自对甲苯硫基、对甲苯亚磺酰基、对甲苯磺酰基中的一种;R 2选自甲基、烷氧羰基和氢中的一种。
- 根据权利要求4所述的二吡咯甲烯-1-酮类化合物的制备方法,其特征在于,所述缩合反应使用的溶剂选自甲醇、乙醇、异丙醇、DMSO、DMF、甲苯、二甲苯、四氢呋喃和甲基四氢呋喃的一种或多种。
- 根据权利要求4所述的二吡咯甲烯-1-酮类化合物的制备方法,其特征在于,所述缩合反应在碱催化下进行,优选地,所述碱选自氢氧化钠、氢氧化钾和DBU中的一种或多种。
- 根据权利要求4所述的二吡咯甲烯-1-酮类化合物的制备方法,其特征在于,控制所述缩合反应温度为15~150℃,优选70~110℃。
- 根据权利要求6所述的二吡咯甲烯-1-酮类化合物的制备方法,其特征在于,式2化合物、式3化合物和碱的摩尔比为1:(0.5~2):(0.2~2),优选为1:(0.8~1.2):(0.5~1)。
- 一种权利要求1所述的二吡咯甲烯-1-酮在制备治疗肿瘤的药物中的用途。
- 权利要求9所述的用途,其特征在于,所述肿瘤为乳腺癌或肺癌。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023528168A JP2023548919A (ja) | 2020-12-22 | 2021-01-26 | ジピロメテン-1-オン系化合物及びその製造方法 |
EP21908280.7A EP4269388A4 (en) | 2020-12-22 | 2021-01-26 | DIPYRROMETHEN-1-ONE COMPOUND AND METHOD OF PREPARING THE SAME |
US18/208,862 US20230322670A1 (en) | 2020-12-22 | 2023-06-12 | Dipyrrolidine-1-one compounds and their preparation method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011527195.7 | 2020-12-22 | ||
CN202011527195.7A CN112645863B (zh) | 2020-12-22 | 2020-12-22 | 二吡咯甲烯-1-酮类化合物及其制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/208,862 Continuation-In-Part US20230322670A1 (en) | 2020-12-22 | 2023-06-12 | Dipyrrolidine-1-one compounds and their preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022134262A1 true WO2022134262A1 (zh) | 2022-06-30 |
Family
ID=75358930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/073783 WO2022134262A1 (zh) | 2020-12-22 | 2021-01-26 | 二吡咯甲烯-1-酮类化合物及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230322670A1 (zh) |
EP (1) | EP4269388A4 (zh) |
JP (1) | JP2023548919A (zh) |
CN (1) | CN112645863B (zh) |
WO (1) | WO2022134262A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112592306B (zh) * | 2020-12-22 | 2024-02-06 | 百顺药业有限公司 | 吡咯啉酮类化合物及其合成方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04264069A (ja) * | 1991-02-15 | 1992-09-18 | Hiromu Nakajima | ビリルビン誘導体 |
-
2020
- 2020-12-22 CN CN202011527195.7A patent/CN112645863B/zh active Active
-
2021
- 2021-01-26 EP EP21908280.7A patent/EP4269388A4/en active Pending
- 2021-01-26 WO PCT/CN2021/073783 patent/WO2022134262A1/zh active Application Filing
- 2021-01-26 JP JP2023528168A patent/JP2023548919A/ja active Pending
-
2023
- 2023-06-12 US US18/208,862 patent/US20230322670A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04264069A (ja) * | 1991-02-15 | 1992-09-18 | Hiromu Nakajima | ビリルビン誘導体 |
Non-Patent Citations (13)
Title |
---|
BULL CHEM. PHARM. BULL. JP., vol. 67, no. 11, 1994, pages 3088 |
BULL CHEM. SOC. JPN., vol. 67, 1994, pages 3088 - 3093 |
EURO J. MED. CHEM., vol. 30, 1995, pages 931 - 942 |
KAKIUCHI TAKASHI, KINOSHITA HIDEKI, INOMATA KATSUHIKO: "Total Synthesis of (±)-Phytochromobilin Starting from Two Pyrrole Derivatives", SYNLETT, vol. 1999, no. Sup. 1, 1 June 1999 (1999-06-01), DE , pages 901 - 904, XP055945973, ISSN: 0936-5214, DOI: 10.1055/s-1999-3105 * |
KINOSHITA HIDEKI , NGWE HLA , KOBORI KAZUHIRO , INOMATA KATSUHIKO: "A New and Convenient Wittig-type Reaction for the Preparation of Pyrromethenone Derivative.", CHEMISTRY LETTERS, vol. 22, no. 8, 31 December 1993 (1993-12-31), JP , pages 1441 - 1442, XP009537769, ISSN: 0366-7022, DOI: 10.1246/cl.1993.1441 * |
KOHORI KAZUHIRO , HASHIMOTO MASAMI , KINOSHITA HIDEKI , INOMATA KATSUHIKO: "A novel synthesis of C/D-rings component of phytochromobilin dimethyl ester", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 67, no. 11, 30 November 1994 (1994-11-30), JP , pages 3088 - 3093, XP009537863, ISSN: 0009-2673, DOI: 10.1246/bcsj.67.3088 * |
LIBOR VÍTEK: "Impact of serum bilirubin on human diseases", PEDIATRICS, vol. 115, no. 5, 1 May 2005 (2005-05-01), US , pages 1411 - 1412, XP009537860, ISSN: 0031-4005, DOI: 10.1542/peds.2004-1796 * |
MEDCHEMCOMM, vol. 8, 2017, pages 1268 - 1274 |
PERKIN I, J CHEM. SOC., 1987, pages 265 - 276 |
See also references of EP4269388A4 |
TAKEDA SHUZO , JAYASUNDERA KRISHANTHI PADMARANI , KAKIUCHI TAKASHI , KINOSHITA HIDEKI , INOMATA KATSUHIKO: "An Efficient Method for the Conversion of 2-Bromo-5-tosylpyrroles to the Corresponding 5-Tosylpyrrolinones as the D-Ring of Phycocyanobilin Derivatives", CHEMISTRY LETTERS, vol. 30, no. 6, 30 June 2001 (2001-06-30), pages 590 - 591, XP055945972, DOI: 10.1246/cl.2001.590 * |
TETRAHEDRON, vol. 42, 1990, pages 7599 |
TIPTON ADRIANNE K., LIGHTNER DAVID A.: "Ein Dihydrotripyrrinon mit intramolekularer Wasserstoffbrückenbindung", MONATSHEFTE FÜR CHEMIE - CHEMICAL MONTHLY, vol. 130, no. 3, 1 March 1999 (1999-03-01), Vienna, pages 425 - 440, XP055946191, ISSN: 0026-9247, DOI: 10.1007/PL00010223 * |
Also Published As
Publication number | Publication date |
---|---|
EP4269388A4 (en) | 2024-06-05 |
CN112645863A (zh) | 2021-04-13 |
CN112645863B (zh) | 2023-07-18 |
JP2023548919A (ja) | 2023-11-21 |
EP4269388A1 (en) | 2023-11-01 |
US20230322670A1 (en) | 2023-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018024208A1 (zh) | Ido1抑制剂及其制备方法和应用 | |
CN112300153B (zh) | 一种杂环化合物、药物组合物和用途 | |
CN110698474B (zh) | 一种α位取代四氢-γ-咔啉类化合物及其制备方法和应用 | |
CN116964058A (zh) | Kras g12d抑制剂及其在医药上的应用 | |
CN111704646B (zh) | 甾体类化合物及其制备方法和用途 | |
CA3178470A1 (en) | Modulators of alpha-1 antitrypsin | |
CN115353508A (zh) | 5-吡啶-1h-吲唑类化合物、药物组合物和应用 | |
WO2022134262A1 (zh) | 二吡咯甲烯-1-酮类化合物及其制备方法 | |
WO2022017317A1 (zh) | 一种规模化合成河豚毒素的方法 | |
EP2233467B1 (en) | Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof | |
CN116283831A (zh) | 一种对硝基苯衍生物及其制备方法和应用 | |
FR2758329A1 (fr) | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique | |
KR100537595B1 (ko) | Gm-95 물질의 제조 방법 | |
CN112479967B (zh) | 胆绿素类化合物及其制备方法和用途 | |
WO2022134259A1 (zh) | 吡咯啉酮类化合物及其合成方法 | |
JP2991348B2 (ja) | 7−(ジフェニルメチル)オキシ−9a−メトキシマイトサン並びにその製造及び使用 | |
CA2166032A1 (fr) | Derives de 1-oxo-2-(phenylsulfonylamino) pentylpiperidine, leur preparation et leur application en therapeutique | |
JP2020528067A (ja) | ステロイド系誘導体fxrアゴニストの結晶又は非晶質、その製造方法及び使用 | |
CN114805168B (zh) | 吡咯啉酮类化合物及其合成方法 | |
JP4903956B2 (ja) | 7−オキサビシクロ[2.2.1]ヘプト−5−エン−2−カルボン酸誘導体の製造方法 | |
SAIGA et al. | Synthesis of 1, 2, 3, 4-tetrahydro-β-carboline derivatives as hepatoprotective agents. IV. Positional isomers of 1, 2, 3, 4-tetrahydro-2-methylthiothiocarbonyl-β-carboline-3-carboxylic acid and its 1-alkylated derivatives | |
US20160362371A1 (en) | Novel tricyclic compounds and preparation thereof | |
JPH0667942B2 (ja) | テトラヒドロ3環式化合物 | |
CN115703712A (zh) | 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物 | |
CN117567457A (zh) | 噻唑酮亚砜和砜类化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21908280 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023528168 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023012371 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112023012371 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230621 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021908280 Country of ref document: EP Effective date: 20230724 |